| Project/Area Number |
15K09634
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders |
|---|
Principal Investigator |
Takahashi Yukitoshi 独立行政法人国立病院機構(静岡・てんかん神経医療センター臨床研究部), その他部局等, その他 (70262764)
|
|---|
| Research Collaborator |
NISHIMURA Shigeko
TAKAO Emiko
KASAI Risa
ENOKIDA Kaoru
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 非ヘルペス性急性辺縁系脳炎 / 免疫病態 / GluN2B抗体 / GluN1抗体 / IgGサブクラス / 活性化補体 / 免疫複合体 / 補体 |
|---|
| Outline of Final Research Achievements |
Results: Before immunomodulation therapy (IT), mean level of C5a of NHALE was higher than that of DCs (p=0.0271), and 36.8% of patients had higher levels than mean+2SD of DCs. Evolution of C5a suggested peak level around 10 days after onsets.
Before IT, mean level of iC3b in NHALE was higher than that of DCs(p<0.0001), and 66.7% of patients had higher levels than mean+2SD of DCs. Evolution of iC3b suggested peak level around 10 days after onsets. Before IT, mean level of MAC in NHALE was higher than that of DCs (p<0.0001), and 51.4% of patients had higher levels than mean+2SD of DCs. The mean level in NHALE was also higher (p=0.0003) after IT. Before & after IT, mean level of CD59 was not different between two groups. Conclusion: In approximately half of NHALE patients, increased activated complements may contribute to the impairment of neuronal cells in acute stage.
|
